⌘K
Loading ticker…
BioAge Labs, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, BioAge Labs, Inc. Common Stock (BIOA) has a 3-month relative strength percentile of 88 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 94. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 7.7%, relative volume 6.61×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 88, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
BIOA is in a stage 2 uptrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 32.2% / 64.5%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
BIOA is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $17M notional. Top 3 carry $36M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $17M |
| IWMiShares Russell 2000 ETF | 0.02% | $13M |
| VXFVanguard Extended Market ETF | 0.01% | $6M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | 1.20% | $4M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $776K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BIOA Jan avg: 11.41% median: 11.41% win: 50% σ: 45.44% n: 2 2024-09-27 → 2026-05-29 | BIOA Feb avg: 9.07% median: 9.07% win: 100% σ: 11.60% n: 2 2024-09-27 → 2026-05-29 | BIOA Mar avg: -20.13% median: -20.13% win: 0% σ: 1.89% n: 2 2024-09-27 → 2026-05-29 | BIOA Apr avg: 4.02% median: 4.02% win: 50% σ: 10.86% n: 2 2024-09-27 → 2026-05-29 | BIOA May avg: -1.55% median: -1.55% win: 50% σ: 5.89% n: 2 2024-09-27 → 2026-05-29 | BIOA Jun avg: 4.29% median: 4.29% win: 100% σ: 0.00% n: 1 2024-09-27 → 2026-05-29 (current) | BIOA Jul avg: 6.54% median: 6.54% win: 100% σ: 0.00% n: 1 2024-09-27 → 2026-05-29 | BIOA Aug avg: 12.04% median: 12.04% win: 100% σ: 0.00% n: 1 2024-09-27 → 2026-05-29 | BIOA Sep avg: 16.43% median: 16.43% win: 100% σ: 4.01% n: 2 2024-09-27 → 2026-05-29 | BIOA Oct avg: 21.10% median: 21.10% win: 100% σ: 10.80% n: 2 2024-09-27 → 2026-05-29 | BIOA Nov avg: 2.51% median: 2.51% win: 50% σ: 32.32% n: 2 2024-09-27 → 2026-05-29 | BIOA Dec avg: -14.90% median: -14.90% win: 50% σ: 76.80% n: 2 2024-09-27 → 2026-05-29 |